Wieliczka

Researchers are evaluating the safety and effectiveness of lebrikizumab in people aged 12 years and older who have chronic rhinosinusitis with nasal polyps and are being treated with intranasal corticosteroids. This Phase 3 study is designed to better understand how lebrikizumab works alongside standard nasal spray treatments over a period of about 18 months. Participants will receive either lebrikizumab or a placebo by subcutaneous injection, while continuing their regular intranasal corticosteroid spray treatment. The study is randomized, double-blind, and placebo-controlled, meaning neither participants nor researchers know who receives the active drug or placebo. The study measures changes from baseline in nasal congestion severity and nasal polyp size using participant reports and endoscopic scoring at the start and after 24 weeks. During the study, participants will undergo evaluations including nasal examinations and symptom assessments at specified times. Researchers will monitor nasal polyp scores and nasal congestion severity to assess treatment impact. Safety and side effects will also be closely observed throughout the study. The total duration of participation is approximately 18 months, allowing careful tracking of treatment outcomes and safety over time.

Researchers are evaluating the effects of pulmonary rehabilitation conducted in the underground Health Resort of the "Wieliczka" Salt Mine on elderly individuals aged 65 and older who have chronic respiratory diseases. The study aims to assess changes in functional capacity, respiratory parameters, and blood rheology in this population. It is a prospective, experimental, controlled study using a crossover design to carefully measure the impact of this unique rehabilitation environment. Participants will undergo a 3-week rehabilitation and treatment stay in the underground salt chambers. Each day, they will participate in 2.5 hours of pulmonary rehabilitation supervised by a doctor, physiotherapist, and nurse. The study includes multiple testing points: initial qualifying tests and measurements 3 weeks before the rehabilitation, repeated tests immediately before the stay, right after completion, and again 3 months later. Throughout the study, researchers will measure respiratory muscle strength using several tests, exercise tolerance with the 6-Minute Walk Test, gait speed, chest mobility, and quality of life using the 15D questionnaire. Blood tests will evaluate rheological properties and inflammatory markers. This comprehensive monitoring extends up to 18 months, including follow-up tests to track long-term effects and safety of the rehabilitation program.